Tocqueville Asset Management L.P. Buys 1,547 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Tocqueville Asset Management L.P. increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 6.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,147 shares of the medical research company's stock after buying an additional 1,547 shares during the quarter. Tocqueville Asset Management L.P.'s holdings in IQVIA were worth $5,138,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. FMR LLC grew its holdings in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after buying an additional 804,963 shares in the last quarter. Cantillon Capital Management LLC grew its holdings in shares of IQVIA by 12.3% during the fourth quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company's stock valued at $406,018,000 after buying an additional 226,017 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock valued at $437,378,000 after buying an additional 583,396 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after buying an additional 452,029 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of IQVIA by 3.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,246,890 shares of the medical research company's stock valued at $245,026,000 after buying an additional 44,991 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Remove Ads

IQVIA Stock Performance

Shares of NYSE IQV traded up $1.59 during trading hours on Friday, hitting $185.85. 3,242,588 shares of the company's stock were exchanged, compared to its average volume of 1,237,438. The company's 50-day moving average price is $194.94 and its 200-day moving average price is $208.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The stock has a market capitalization of $32.77 billion, a price-to-earnings ratio of 24.78, a PEG ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $254.80.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Bank of America lowered their target price on IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research note on Friday, December 13th. Stephens assumed coverage on IQVIA in a research note on Friday, December 20th. They issued an "overweight" rating and a $250.00 target price on the stock. UBS Group lowered their target price on IQVIA from $260.00 to $255.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Truist Financial restated a "buy" rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.